Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna
Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has had some challenges this year. From production issues to some disquieting reports of blood clots possibly being linked to the vaccine, it hasn't been the success the company was likely hoping it would be at this stage. Vaccines from Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have generated far more revenue for those companies and appear to be the vaccines of choice for many people.
However, the delta variant may change that, as both Moderna and Pfizer are suggesting booster shots are necessary. And the Food and Drug Administration (FDA) recently authorized a third dose for people with weakened immune systems. Meanwhile, a new study has found the Johnson & Johnson vaccine to be highly effective against the delta variant, so booster shots may not be necessary for individuals who receive that vaccine. While a lack of boosters won't translate to more revenue from the vaccine, it's a development that could ultimately lead to Johnson & Johnson's vaccine rising in popularity and grabbing more market share.
Image source: Getty Images.
Source Fool.com
